All lobbying filings

ASTELLAS PHARMA US, INC.

Lobbying for ASTELLAS PHARMA US, INC.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Illinois · House · Senate · $560,000.00 expenses · posted Apr 21, 2025

Official filing document

Bills named in this filing 4

HR 1300
PSA Screening for HIM Act
S 297
PSA Screening for HIM Act
HR 5376
Impacts and Outcomes for Health Career Training Act
S 392
Sloan Canyon Conservation and Lateral Pipeline Act

Lobbying activity 4

Medicare/Medicaid

Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1300/S. 297 PSA screening bills; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills).

Health Issues

Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; Issues related to implementation of the Inflation Reduction Act (H.R. 5376).

Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).

Insurance

Issues related to Pharmacy Benefit Manager reform, S. 392 Give Kids a Chance Act; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.